Suppr超能文献

巨噬细胞衍生趋化因子 MDC/CCL22:COVID-19 中的一个模棱两可的发现。

Macrophage-Derived Chemokine MDC/CCL22: An Ambiguous Finding in COVID-19.

机构信息

Laboratory of Molecular Immunology, Saint Petersburg Pasteur Institute, Mira St. 14, 197101 St. Petersburg, Russia.

Department of Immunology, Pavlov First State Medical University of St. Petersburg, L'va Tolstogo St. 6-8, 197022 St. Petersburg, Russia.

出版信息

Int J Mol Sci. 2023 Aug 23;24(17):13083. doi: 10.3390/ijms241713083.

Abstract

Macrophage-derived chemokine (MDC/CCL22) is a chemokine of the C-C subfamily. It is involved in T-cellular maturation and migration. Our previous research shows that plasma CCL22/MDC tends to show a statistically significant depletion of concentrations in acute patients and convalescents when compared to healthy donors. In the current work, we investigate existing views on MDC/CCL22 dynamics in association with various pathologies, including respiratory diseases and, specifically, COVID-19. Additionally, we present our explanations for the observed decrease in MDC/CCL22 concentrations in COVID-19. The first hypothesis we provide implies that viral products bind to MDC/CCL22 and block its activity. Another explanation for this phenomenon is based on dendritic cells population and the inhibition of their function.

摘要

巨噬细胞来源的趋化因子(MDC/CCL22)是 C-C 亚家族的趋化因子。它参与 T 细胞的成熟和迁移。我们之前的研究表明,与健康供体相比,急性患者和恢复期患者的血浆 CCL22/MDC 浓度趋于明显减少。在目前的工作中,我们研究了与各种病理相关的 MDC/CCL22 动力学的现有观点,包括呼吸道疾病,特别是 COVID-19。此外,我们还解释了 COVID-19 中观察到的 MDC/CCL22 浓度下降的原因。我们提供的第一个假设表明,病毒产物与 MDC/CCL22 结合并阻断其活性。另一种解释基于树突状细胞群体及其功能抑制。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/da03/10487728/3676cf1e7cc1/ijms-24-13083-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验